ArticleTranslational oncology2020
Development of a Microfluidic Culture Paradigm for Ex Vivo Maintenance of Human Glioblastoma Tissue: A New Glioblastoma Model?
Article in Translational oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Time-dependent cytokine landscapes in an ex vivo microfluidic glioblastoma platform.Cancer immunology, immunotherapy : CII · 2026Article
- Investigating the Secreted Proteome of Primary and Metastatic Human Brain Tumour Explants Maintained on a Miniaturised Perfusion Device.Current oncology (Toronto, Ont.) · 2026Article
- Translational Models for Glioblastoma: Revolutionizing Drug Development and Personalized Medicine through Clinical Insights.Theranostics · 2026Review
- Review
- Integrating computational fluid dynamics into organ-on-chip systems: a glioblastoma-centred design and validation framework.Frontiers in bioengineering and biotechnology · 2025Review
- Biosensor-Enhanced Organ-on-a-Chip Models for Investigating Glioblastoma Tumor Microenvironment Dynamics.Sensors (Basel, Switzerland) · 2024Review
- Use and application of organ-on-a-chip platforms in cancer research.Journal of cell communication and signaling · 2023Review
- Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues.International journal of molecular sciences · 2023Review
- Article
- Identification of RUNX1 and IFNGR2 as prognostic-related biomarkers correlated with immune infiltration and subtype differentiation of low-grade glioma.Biomolecules & biomedicine · 2023Article
- Glioblastoma-on-a-chip construction and therapeutic applications.Frontiers in oncology · 2023Review
- How to build a tumor: An industry perspective.Drug discovery today · 2022Review
- Development of a microfluidic platform to maintain viability of micro-dissected tumor slices in culture.Biomicrofluidics · 2022Article
- Review
- Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development.Journal of translational medicine · 2021Article
- Glioma-on-a-Chip Models.Micromachines · 2021Article
- Review
- Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas.Frontiers in molecular neuroscience · 2021Article
- Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments.Frontiers in oncology · 2020Review
- Microfluidics for interrogating live intact tissues.Microsystems & nanoengineering · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundOne way to overcome the genetic and molecular variations within glioblastoma is to treat each tumour on an individual basis. To facilitate this, we have developed a microfluidic culture paradigm that maintains human glioblastoma tissue ex vivo.
methodsThe assembled device, fabricated using a photolithographic process, is composed of two layers of glass bonded together to contain a tissue chamber and a network of microchannels that allow continued tissue perfusion.
resultsA total of 128 tissue biopsies (from 33 patients) were maintained in microfluidic devices for an average of 72 hours. Tissue viability (measured with Annexin V and propidium iodide) was 61.1% in tissue maintained on chip compared with 68.9% for fresh tissue analysed at commencement of the experiments. Other biomarkers, including lactate dehydrogenase absorbance and trypan blue exclusion, supported the viability of the tissue maintained on chip. Histological appearances remained unchanged during the tissue maintenance period, and immunohistochemical analysis of Ki67 and caspase 3 showed no significant differences when compared with fresh tissues. A trend showed that tumours associated with poorer outcomes (recurrent tumours and Isocitrate Dehydrogenase - IDH wildtype) displayed higher viability on chip than tumours linked with improved outcomes (low-grade gliomas, IDH mutants and primary tumours).
conclusionsThis work has demonstrated for the first time that human glioblastoma tissue can be successfully maintained within a microfluidic device and has the potential to be developed as a new platform for studying the biology of brain tumours, with the long-term aim of replacing current preclinical GBM models and facilitating personalised treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.